Atara Biotherapeutics, Inc.

Atara Biotherapeutics develops cell-based treatments for cancer and autoimmune diseases. Their main product, Tab-cel, is a therapy made from immune cells that is being tested to treat a type of cancer called post-transplant lymphoproliferative disease, which can develop after organ transplants. They are also working on another cell therapy called ATA3219 designed to fight B-cell cancers and autoimmune conditions. The company collaborates with major cancer research centers including Memorial Sloan Kettering Cancer Center.